Healthcare Sales & Marketing Network News: Digoxin

Searching News Database: Digoxin

HSMN NewsFeed - 12 Nov 2018
Lannett Enters Into Agreement With Amneal Pharmaceuticals For Levothyroxine
Biopharmaceuticals Generics Distribution

HSMN NewsFeed - 30 Oct 2018
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 11 Oct 2018
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Aug 2018
Lannett Provides Update On Contract Renewal With Jerome Stevens Pharmaceuticals
Biopharmaceuticals Generics Licensing Distribution

HSMN NewsFeed - 29 May 2018
Egalet Announces Large Regional Plan to Cover SPRIX(R) Nasal Spray
Biopharmaceuticals Reimbursement

HSMN NewsFeed - 12 Feb 2018
Ferring's CLENPIQ(TM) (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep Now Available
Biopharmaceuticals Gastroenterology Product Launch

HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology

HSMN NewsFeed - 6 Sep 2017
Actelion Receives FDA Approval Of TRACLEER(R) (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Sep 2016
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA

HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Feb 2014
Covis Pharmaceuticals Announces Its New Expanded Dosage Options of LANOXIN(R) for Cardiac Patients With Mild-to-Moderate Heart Failure
Biopharmaceuticals Cardiology

HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 8 Nov 2013
Eisai Announces Availability of ACIPHEX(R) Sprinkle(TM) (Rabeprazole Sodium) for Treatment of GERD in Children Ages 1 to 11
Biopharmaceuticals Gastroenterology Product Launch

HSMN NewsFeed - 31 Jul 2013
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on Findings of Reduced Rate of Stent Thrombosis With BRILINTA (ticagrelor)
Biopharmaceuticals Devices Interventional Cardiology

HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Jan 2013
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Jun 2012
Actelion Pharmaceuticals Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application for Second Generation VELETRI(R) (epoprostenol) for Injection
Biopharmaceuticals FDA

HSMN NewsFeed - 22 Dec 2011
Covis Pharma to Acquire U.S. Rights from GlaxoSmithKline for Fortaz(R), Zinacef(R), Lanoxin(R), Parnate(R), and Zantac(R) Injection
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 7 Feb 2011
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include Data Supporting the Recommended Adult Dose of REYATAZ/ritonavir 300/100 mg for HIV-1 Infected Pregnant Women
Biopharmaceuticals HIV/AIDS FDA

HSMN NewsFeed - 29 Jul 2010
Shionogi Inc. Announces FDA Approval of CUVPOSA for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
Biopharmaceuticals FDA

HSMN NewsFeed - 3 May 2010
FDA Approved VIMOVO(TM) for Arthritis Patients at Risk of Developing NSAID-Associated Gastric Ulcers
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 9 Feb 2010
Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors With Plavix(R) (Clopidogrel Bisulfate)
Biopharmaceuticals

HSMN NewsFeed - 29 Jan 2010
Teva UK Limited Launches Lercanidipine Hydrochloride Film-Coated Tablets
Biopharmaceuticals Generics

HSMN NewsFeed - 4 May 2009
AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
Biopharmaceuticals

HSMN NewsFeed - 23 Feb 2009
KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD
Biopharmaceuticals

HSMN NewsFeed - 31 Jan 2009
FDA Approves KAPIDEX(TM) (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 21 Jul 2008
FDA Clears Osmetech's Warfarin Sensitivity Test and New eSensor(R) XT-8 Platform
Diagnostics FDA

HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 28 Jan 2008
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Biopharmaceuticals HIV/AIDS Regulatory

HSMN NewsFeed - 20 Jul 2007
Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
Biopharmaceuticals Regulatory HIV/AIDS

HSMN NewsFeed - 12 Jun 2007
July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals

HSMN NewsFeed - 2 May 2007
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Apr 2007
BROVANA(TM) Inhalation Solution Now Available by Prescription for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals

HSMN NewsFeed - 25 Mar 2007
EVEREST Data on Short- and Long-Term Use of Otsuka's Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials
Biopharmaceuticals Cardiology

HSMN NewsFeed - 2 Mar 2007
Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in Canada
Biopharmacetuicals

HSMN NewsFeed - 22 Feb 2007
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
Biopharmaceuticals

HSMN NewsFeed - 26 Jan 2007
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
Biopharmaceuticals

HSMN NewsFeed - 27 Nov 2006
FDA Accepts as "Complete Response" Oscient Pharmaceuticals' Submission Following FACTIVE Approvable Letter for Five-Day CAP
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Nov 2006
XOPENEX HFA(R) Data Presented at American College of Allergy, Asthma and Immunology Annual Meeting
Biopharmaceuticals

HSMN NewsFeed - 23 Oct 2006
Data for XOPENEX(R) Brand of Levalbuterol Presented at American College of Chest Physicians Annual Conference
Biopharmaceuticals

HSMN NewsFeed - 13 Oct 2006
Data on FACTIVE(R) Tablets Short-Course Therapy in Patients with Co-Morbidities Presented at Annual Meeting of Infectious Diseases Society of America
Biopharmaceuticals

HSMN NewsFeed - 22 Sep 2006
Oscient Pharmaceuticals Receives Approvable Letter from FDA for FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA

HSMN NewsFeed - 13 Sep 2006
Oscient Pharmaceuticals Announces Results of FDA Advisory Committee Meeting for FACTIVE Tablets for the Treatment of Acute Bacterial Sinusitis
Biopharmaceuticals FDA

HSMN NewsFeed - 28 Jun 2006
Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory Committee to Address sNDA for Five-Day Treatment of Acute Bacterial Sinusitis with FACTIVE Tablets
Biopharmaceuticals FDA

Return to NewsFeed

Additional items found! 22

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 22 additional stories matching:
Digoxin
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!